Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient

Transplant International

Volumn 22, Issue 2, 2009, Pages 172-181

  Kalambokis, Georgios ^a   Manousou, Pinelopi ^a   Samonakis, Dimitrios ^a   Grillo, Federica ^a   Dhillon, Amar P ^a   Patch, David ^a   O'Beirne, James ^a   Rolles, Keith ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Clinical outcome; Graft cirrhosis; Hepatitis C; Liver transplantation

Indexed keywords

ALBUMIN; AZATHIOPRINE; CYCLOSPORIN; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG USE; DRUG WITHDRAWAL; EVALUATION; FEMALE; FOLLOW UP; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRESSURE GRADIENT; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SURVIVAL; VENOUS PRESSURE;

ADULT; AGED; FEMALE; GRAFT SURVIVAL; HEPATIC VEINS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME; VENOUS PRESSURE;

EID: 58149280164     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00744.x     Document Type: Article

References (45)

1. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001 35 : 666.
2. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996 334 : 815.
3. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992 103 : 317.
4. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000 32 : 673.
5. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997 112 : 463.
6. Feray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994 20 : 1137.
7. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349 : 825.
8. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999 29 : 250.
9. Papatheodoridis GV, Patch D, Dusheiko GM, Burroughs AK. The outcome of hepatitis C virus infection after liver transplantation - is it influenced by the type of immunosuppression? J Hepatol 1999 30 : 731.
10. Papatheodoridis GV, Davies S, Dhillon AP, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001 72 : 412.
11. Samonakis DN, Triantos CK, Thalheimer U, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005 11 : 386.
12. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995 108 : 1088.
13. Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996 24 : 1041.
14. Vargas HE, Laskus T, Wang LF, et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 1998 4 : 22.
15. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002 36 : 202.
16. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003 38 : 34.
17. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000 32 : 852.
18. Saab S, Niho H, Comulada S, et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver Int 2005 25 : 940.
19. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003 37 : 902.
20. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007 133 : 481.
21. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985 5 : 419.
22. Morali GA, Sniderman KW, Deitel KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992 16 : 249.
23. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998 114 : 1296.
24. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005 353 : 2254.
25. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003 38 (Suppl. 1 S54.
26. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006 43 : 492.
27. Burroughs AK, Groszmann R, Bosch J, et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002 50 : 425.
28. Cholongitas E, Quaglia A, Samonakis D, et al. Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut 2006 55 : 1789.
29. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696.
30. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004 39 : 280.
31. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002 360 : 1119.
32. Samonakis DN, Mela M, Quaglia A, et al. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl Infect Dis 2006 8 : 3.
33. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289.
34. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol 2003 38 : 223.
35. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998 27 : 1435.
36. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006 44 : 217.
37. Samonakis DN, Cholongitas E, Thalheimer U, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 2007 13 : 1305.
38. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994 19 : 13.
39. Pozzato G, Kaneko S, Moretti M, et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994 43 : 291.
40. Gigou M, Roque-Afonso AM, Falissard B, Penin F, Dussaix E, Feray C. Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation. J Virol 2001 75 : 11292.
41. Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004 313 : 42.
42. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003 38 : 1282.
43. Frizell E, Abraham A, Doolittle M, et al. FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats. Gastroenterology 1994 107 : 492.
44. Ikeda H, Fujiwara K. Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro. Hepatology 1995 21 : 1161.
45. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007 13 : 21.